1. Fan F, Schimming A, Jaeger D, et al. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012; 2012: 281261.
2.
Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-815.
3.
Zhang W, Huang P. Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol Ther 2011; 11: 150-156.
4.
Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
5.
Yuan Y, Jiang Y, Sun C, et al. Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep 2016; 35: 2499-2515.
6.
Chao X, Liu L, Sun P, et al. Immune parameters associated with survival in metaplastic breast cancer. Breast Cancer Res 2020; 22: 92.
7.
Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
8.
Hendry S, Salgado R, Gevaert T, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol 2017; 24: 311-335.
9.
Kashiwagi S, Asano Y, Goto W, et al. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One 2017; 12: e0170634.
10.
Denkert C, Loibl S, Noske A, et al. Tumor Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
11.
Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550.
12.
Loi S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol 2014; 32: 2935-2937.
13.
Matsumoto H, Koo SL, Dent R, et al. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 2015; 68: 506–510.
14.
Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
15.
Liu, F, Lang, R, Zhao, J. et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011; 130: 645-655.
16.
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
17.
WHO Classification of Tumours Editorial Board. WHO Classification of Tumours 5th Edition: Breast tumours. 2019; 9-161.
18.
Kim JB, Stein R, O'Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 2005; 26: 173-185.
19.
Adams S, Goldstein LJ, Sparano JA, et al. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 2015; 4: e985930.
20.
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50.
21.
Gao Zh, Li Cx, Liu M, et al. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer 2020; 20: 1150.
22.
Saraiva DP, Guadalupe Cabral M, Jacinto A, et al. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open 2017; 2: e000208.
23.
Fan Y, He S. The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. Cancer Manag Res 2022; 14: 1-17.
24.
West NR, Kost SE, Martin SD, et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2013; 108: 155-162.
25.
Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949.
26.
Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 2015; 17: 124.
27.
Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7: 651-658.
28.
Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14: 2413-2420.
29.
Liang Y, Lü W, Zhang X, et al. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer. Diagnostic Pathol 2018; 13: 93.
30.
Oda N, Shimazu K, Naoi Y, et al. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat 2012; 136: 107-116.
31.
Lehmann BD, Jovanović B, Chen X, et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One 2016; 11: e0157368.
32.
Han Li, Liping Li, Huifang Mei, et al. Antitumor properties of triptolide: phenotype regulation of macrophage differentiation. Cancer Biol Ther 2020; 21: 178-188.
33.
Zhang Y, Wang S, Yang B, et al. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. Cancer Biol Med 2019; 16: 350-360.
34.
Azarsiz E, Karaca NE, Aksu G, et al. Reference values for B-cell surface markers and co-receptors associated with primary immune deficiencies in healthy Turkish children. Int J Immunopathol and Pharmacol 2017; 30: 194-200.
35.
Shen M, Wang J, Ren X. New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms. Front Immunol 2018; 9: 470.
36.
Guan H, Lan Y, Wan Y, et al. PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer. Oncoimmunology 2015; 5: e1075112.
37.
Brown JR, Wimberly H, Lannin DR, et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2014; 20: 5995-6005.
38.
Kind S, Merenkow C, Büscheck F, et al. Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. Dis Markers 2019; 2019: 4928315.
39.
Thuy L, Nguyen MD, William E, et al. Syndecan-1 Overexpression Is Associated With Nonluminal Subtypes and Poor Prognosis in Advanced Breast Cancer. Am J Clin Pathol 2013; 140: 468-474.
40.
Schönfeld K, Herbener P, Zuber C, et al. Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models. Pharm Res 2018; 35: 118.
41.
Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
42.
Gordon S, Taylor P. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
43.
Zhou J, Tang Z, Gao S, et al. Tumor-Associated Macrophages: Recent Insights and Therapies. Front Oncol 2020; 10: 188.
44.
Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol 2017; 10: 58.
45.
Hollmén M, Karaman S, Schwager S, et al. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology 2015; 5: 3.
46.
Liu L, Wu Y, Zhang CH, et al, Cancer-associated adipocyte-derived G-CSF promotes breast cancer malignancy via Stat3 signaling. J Mol Cell Biol 2020; 12: 723-737.
47.
He KF, Zhang L, Huang CF, et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int 2014; 2014: 838632.
48.
Kopeć-Szlęzak J. Makrofagi i ich rola w układzie krwiotwórczym. J Transf Med 2014; 7: 84-92.
49.
Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 2014; 63: 395-406.
50.
Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clinl Invest 2007; 117(5): 1155-1166.
51.
Ibrahim SA, Hassan H, Vilardo L, et al. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One 2013; 8: e85737.
52.
Medrek C, Pontén F, Jirström K, et al. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012; 12: 306.
53.
Yaal-Hahoshen N, Azenshtein E, Shina S, et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: A basis for tumor-promoting interactions. Cytokine 2008; 44: 191-200.
54.
Wu Q, Li B, Li Z. et al. Cancer-associated adipocytes: key players in breast cancer progression. J Hematol Oncol 2019; 12: 95.
55.
Carron EC, Homra S, Rosenberg J, et al. Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget 2017; 8: 50731-50746.
56.
Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344: 921-925.
57.
Yuan ZY, Luo RZ, Peng RJ, et al. High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets and Therapy 2014; 7: 1475-1480.
58.
Ding J, Jin W, Chen C, et al. Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer. PLoS One 2012; 7: e41942.
59.
Sousa, S., Brion, R., Lintunen, et al. Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res 2015; 17: 101.
60.
Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007; 39: 2153-2160.
61.
Al Moustafa AE. Epithelial-mesenchymal transition and its regulators are major targets of triple-negative breast cancer. Cell Adh Migr 2013; 7: 424-425.
62.
Zhang WJ, Wang XH, Gao ST, et al. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. J Surg Res 2018; 222: 93-101.
63.
Prat A, Parker J, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
64.
Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30: 1879-1887.
65.
Ye, J, Wang XH, Shi J, et al. Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer. J Cancer 2021; 12: 2886-2892.
66.
Alves AM, Diel LF, Lamers ML. Macrophages and prognosis of oral squamous cell carcinoma: A systematic review. J Oral Path Med 2018; 47: 460-467.
67.
Minami K, Hiwatashi K, Ueno S, et al. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 2018; 15: 4465-4476.
68.
Liu L, Ye Y, Zhu X. MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway. Biomed Pharmacother 2019; 117: 109096.
69.
Kostine M, Briaire-de Bruijn IH, Cleven AHG, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. Oncoimmunology 2017; 7: e1386828.
70.
Gomez-Brouchet A, Illac C, Gilhodes J, et al. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology 2017; 6: e1331193.
71.
Hanna, SJ, McCoy-Simandle K, Leung E, et al. Tunneling nanotubes, a novel mode of tumor cell-macrophage communication in tumor cell invasion. H Cell Sci 2019; 132: jcs223321.
72.
Saha T, Dash C, Jayabalan R, et al. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. Nat Nanotechnol 2022; 17: 98-106.
73.
Tan J, Buache E, Chenard MP, et al. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol 2011; 55: 851-859.
74.
Wang YY, Lehuede C, Laurent V, et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett 2012; 324: 142-151.
75.
Nieman KM, Romero IL, Van Houten B, et al. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013; 1831: 1533-1541.
76.
Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011; 71: 2455-2465.
77.
Rybinska I, Mangano N, Tagliabue E, et al. Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. Int J Mol Sci 2021; 22: 3775.
78.
Ando S, Barone I, Giordano C, et al. The multifaceted mechanism of leptin signaling within tumor microenvironment in driving breast cancer growth and progression. Front Oncol 2014; 4: 340.
79.
Wu Q, Li B, Li J, et al. Cancer-associated adipocytes as immunomodulators in cancer. Biomark Res 2021; 9: 2.
80.
Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Canc Res Treat 2013; 137: 307-314.
81.
Harborg S, Zachariae R, Olsen J, et al. Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis. Npj Breast Cancer 2021; 7: 119.
82.
Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002; 13: 741-51.
83.
Kaul K, Misri S, Ramaswamy B, et al. Contribution of the tumor and obese microenvironment to triple negative breast cancer, Cancer Lett 2021; 509: 115-120.
84.
Apostolopoulos V, de Courten MP, Stojanovska L, et al. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res 2016; 60: 43-57.
85.
Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008; 114: 71-83.
86.
Reis BS, Lee K, Fanok MH, et al. Leptin receptor signaling in T cells is required for Th17 differentiation. J Immunol 2015; 194: 5253-5260.
87.
De Rosa V, Procaccini C, Calì G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 2: 241-255.
88.
Girgert R, Emons G, Gründker C. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib. Oncol Rep 2017; 37: 1212-1218.
89.
Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344: 921-925.
90.
Elenbaas B, Weinberg RA. Heterotypic Signaling between Epithelial Tumor Cells and Fibroblasts in Carcinoma Formation, Exp Cell Res 2001; 264: 169-184.
91.
Luo H, Tu G, Liu Z, et al. Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Lett 2015; 361: 155-163.
92.
Liao D, Luo Y, Markowitz D. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model, PLoS One 2009; 4: e7965.
93.
Zhou J, Wang XH, Zhao YX, et al. Cancer-Associated Fibroblasts Correlate with Tumor-Associated Macrophages Infiltration and Lymphatic Metastasis in Triple Negative Breast Cancer Patients. J Cancer 2018; 9: 4635-4641.
94.
Wang M, Zhang J, Huang Y, et al. Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells. Med Sci Monit 2017; 23: 3904-3912.
95.
Sun WY, Lee YK, Koo JS. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med 2016; 14: 173.
96.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
97.
Mori H, Kubo M, Yamaguchi R, et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget 2017; 8: 15584-15592.
98.
Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 Expression in Triple-Negative Breast Cancer Cancer Immunol Res 2014; 2: 361-370.
99.
Cimino-Mathews A. Tumor-infiltrating lymphocytes and PD-L1 in breast cancer (and, what happened to medullary carcinoma?).Diag Histopathol 2021; 27: 148-154.
100.
Sfanos KS, Bruno TC, Meeker AK, et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009; 69: 1694-1703.
101.
Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
102.
Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. NActa Histochem 2006; 108: 19-24.
103.
Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget 2017; 8: 31347-31354.
104.
Dieci MV, Tsvetkova V, Griguolo G, et al. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Eur J Cancer 2020; 136: 7-15.
105.
Mori H, Kubo M, Yamaguchi R, et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget 2017; 8: 15584-15592.
